29224

544292

ONESOURCE

img img img img
No Data Available

ONESOURCE SPECL PHARMA L Share Price Update

As of the latest trading session, ONESOURCE SPECL PHARMA L is trading at ₹1779.3, down by ₹-27.50 or -1.52% from its previous close. The stock has moved between ₹1773.00 and ₹1803.00 today. Over the past year, the stock has delivered a return of 9.85%. In the last month, it has returned 13.87%.

ONESOURCE SPECL PHARMA L performance

Today’s low Today’s high
₹ 1773.00 ₹ 1803.00
₹ 1777.00
52 week low 52 week high
₹ 1057.00 ₹ 2248.00
₹ 1777.00
Open Price ₹ 1800.00
Prev. Close ₹ 1806.80
Volume (Shares) 25269.00
Total traded value ₹ 449.03
Upper Circuit ₹ 2168.10
Lower Circuit ₹ 1445.50
info

Investment Returns

Over 1 Month 13.87% Over 3 Months 38.55% Over 6 Months 14.77% Over 1 Year 9.85%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ONESOURCE SPECL PHARMA L fundamentals


  • Market cap (Cr) 20,417.30
  • P/E Ratio (TTM) 978.00
  • Beta -0.13
  • Book Value / share 519.00
  • Return on equity 3.22%
  • EPS (TTM) 2.32
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.48
info icon alternate text
  • Market cap (Cr) 20,408.10
  • P/E Ratio (TTM) 978.00
  • Beta -0.10
  • Book Value / share 519.00
  • Return on equity 3.22%
  • EPS (TTM) 2.32
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 21.48
info icon alternate text

ONESOURCE SPECL PHARMA L Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 418.96
Operating Expense 401.24
Net Profit 21.48
Net Profit Margin (%) 5.12
Earnings Per Share (EPS) 1.87
EBITDA 78.47
Effective Tax Rate (%) 0.00
Particulars DEC 2025 (Values in Cr)
Revenue 290.22
Operating Expense 349.94
Net Profit -62.19
Net Profit Margin (%) -21.42
Earnings Per Share (EPS) -5.43
EBITDA 10.37
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 375.19
Operating Expense 341.12
Net Profit 37.10
Net Profit Margin (%) 9.88
Earnings Per Share (EPS) 3.24
EBITDA 104.62
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 321.01
Operating Expense 301.45
Net Profit 24.82
Net Profit Margin (%) 7.73
Earnings Per Share (EPS) 2.17
EBITDA 85.13
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 477.41
Operating Expense 306.44
Net Profit 174.19
Net Profit Margin (%) 36.48
Earnings Per Share (EPS) 15.22
EBITDA 240.85
Effective Tax Rate (%) 0.00
Particulars MAR 2026 (Values in Cr)
Revenue 1405.38
Operating Expense 1393.76
Net Profit 21.21
Net Profit Margin (%) 1.50
Earnings Per Share (EPS) 1.85
EBITDA 278.59
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1299.59
Operating Expense 1226.48
Net Profit 19.31
Net Profit Margin (%) 1.48
Earnings Per Share (EPS) 1.75
EBITDA 274.70
Effective Tax Rate (%) 193.19
Particulars MAR 2024 (Values in Cr)
Revenue 171.92
Operating Expense 425.15
Net Profit -390.40
Net Profit Margin (%) -227.08
Earnings Per Share (EPS) -93.97
EBITDA -199.21
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 38.71
Operating Expense 312.56
Net Profit -799.11
Net Profit Margin (%) -2064.35
Earnings Per Share (EPS) -200.69
EBITDA -316.32
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 513.90
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.21
EBITDA Margin 33.51
Particulars MAR 2024 (Values in Cr)
Book Value / Share 98.68
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.21
EBITDA Margin -34.39
Particulars MAR 2023 (Values in Cr)
Book Value / Share 195.87
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.14
EBITDA Margin -285.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 333.49
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.88
EBITDA Margin -0.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 5029.28
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.72
EBITDA Margin -328.85
Particulars MAR 2025 (Values in Cr)
Book Value / Share 517.36
ROE % 3.22
ROCE % 5.21
Total Debt to Total Equity 0.24
EBITDA Margin 29.71
Particulars MAR 2024 (Values in Cr)
Book Value / Share 99.19
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.21
EBITDA Margin -45.51
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1961.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.12
EBITDA Margin -298.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 259.75
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.86
EBITDA Margin -69.15
Particulars MAR 2021 (Values in Cr)
Book Value / Share 5045.70
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.72
EBITDA Margin -332.12
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 300.89
Total Assets 7550.24
Total Liabilities 7550.24
Total Equity 5880.57
Share Outstanding 11
Price to Book Ratio 3.38
Return on Assets (%) -0.23
Return on Capital (%) -0.27
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.32
Total Assets 1308.61
Total Liabilities 1308.61
Total Equity 395.71
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) -29.89
Return on Capital (%) -40.84
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 79.82
Total Assets 2008.80
Total Liabilities 2008.80
Total Equity 785.45
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) -39.81
Return on Capital (%) -49.31
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 169.73
Total Assets 2442.35
Total Liabilities 2442.35
Total Equity 1012.47
Share Outstanding 2
Price to Book Ratio 0.00
Return on Assets (%) -9.46
Return on Capital (%) -10.67
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 77.76
Total Assets 1257.80
Total Liabilities 1257.80
Total Equity 776.02
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) -9.60
Return on Capital (%) -10.4
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 227.62
Total Assets 7390.46
Total Liabilities 7390.46
Total Equity 5920.10
Share Outstanding 11
Price to Book Ratio 3.38
Return on Assets (%) 0.26
Return on Capital (%) 0.29
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.25
Total Assets 1308.57
Total Liabilities 1308.57
Total Equity 397.74
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) -29.83
Return on Capital (%) -40.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 79.76
Total Assets 2008.44
Total Liabilities 2008.44
Total Equity 786.71
Share Outstanding 4
Price to Book Ratio 0.00
Return on Assets (%) -39.78
Return on Capital (%) -49.22
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 169.45
Total Assets 2444.99
Total Liabilities 2444.99
Total Equity 1015.50
Share Outstanding 3
Price to Book Ratio 0.00
Return on Assets (%) -9.39
Return on Capital (%) -10.59
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 77.40
Total Assets 1262.17
Total Liabilities 1262.17
Total Equity 778.55
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) -9.60
Return on Capital (%) -10.41
Particulars MAR 2025 (Values in Cr)
Net Income -67.75
Cash from Operations -60.84
Cash from Investing -201.08
Cash from Financing 412.00
Net change in Cash 143.07
Free Cash Flow 67.30
Particulars MAR 2024 (Values in Cr)
Net Income -391.16
Cash from Operations -107.21
Cash from Investing 510.54
Cash from Financing -390.54
Net change in Cash 12.79
Free Cash Flow -43.44
Particulars MAR 2023 (Values in Cr)
Net Income -799.83
Cash from Operations -173.81
Cash from Investing -67.71
Cash from Financing 118.31
Net change in Cash -112.28
Free Cash Flow -129.81
Particulars MAR 2022 (Values in Cr)
Net Income -231.16
Cash from Operations -415.88
Cash from Investing -691.60
Cash from Financing 1161.96
Net change in Cash 54.47
Free Cash Flow 239.26
Particulars MAR 2021 (Values in Cr)
Net Income -120.56
Cash from Operations -116.71
Cash from Investing -207.37
Cash from Financing 380.95
Net change in Cash 56.00
Free Cash Flow 90.72
Particulars MAR 2025 (Values in Cr)
Net Income -22.14
Cash from Operations -40.38
Cash from Investing -300.03
Cash from Financing 417.21
Net change in Cash 69.89
Free Cash Flow 45.92
Particulars MAR 2024 (Values in Cr)
Net Income -390.40
Cash from Operations -108.98
Cash from Investing 505.98
Cash from Financing -384.22
Net change in Cash 12.78
Free Cash Flow -45.22
Particulars MAR 2023 (Values in Cr)
Net Income -799.11
Cash from Operations -175.62
Cash from Investing -65.68
Cash from Financing 118.31
Net change in Cash -112.05
Free Cash Flow -133.78
Particulars MAR 2022 (Values in Cr)
Net Income -229.74
Cash from Operations -419.66
Cash from Investing -684.53
Cash from Financing 1158.74
Net change in Cash 54.54
Free Cash Flow 229.94
Particulars MAR 2021 (Values in Cr)
Net Income -121.23
Cash from Operations -114.87
Cash from Investing -210.33
Cash from Financing 380.97
Net change in Cash 55.75
Free Cash Flow 44.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 13.67 1.60 253.43 23.12 40.00
BLISS GVS PHARMA LTD. 300.20 24.29 2.66 3175.78 118.35 304.30
CIPLA LTD 1398.95 27.70 3.28 113007.26 1165.55 1672.20
FERMENTA BIOTECH LIMITED 302.65 10.07 2.27 890.73 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 23.13 4.26 253.43 23.12 40.00
AMRUTANJAN HEALTH CARE LTD. 558.20 25.02 4.35 1613.79 490.00 789.95
ASTRAZENECA PHARMA IND LT 8604.25 103.40 26.92 21510.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 300.20 32.28 2.74 3175.78 118.35 304.30

ONESOURCE SPECL PHARMA L shareholding pattern

Holding
31.4%
30.48%
17.49%
20.6%
38.38%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

ONESOURCE SPECL PHARMA L Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1780.90 -1.43 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 1831.30
  • 26 Days 1752.00
  • 10 Days 1824.30
  • 50 Days 1662.00
  • 12 Days 1817.80
  • 100 Days 1610.60
  • 20 Days 1781.30
  • 200 Days 1620.10
1843.13 PIVOT
First Support 1812.37 First Resistance 1865.27 Second Support 1790.23 Second Resistance 1896.03 Third Support 1759.47 Third Resistance 1918.17
RSI 61.99 ADX 55.29 MACD 72.22 Williams % R -42.52 Commodity Channel Index (CCI) 79.05
Date 2026-05-22 Week 97707.00 Same Day 54905.00 Month 237901.00
1 Year -0.13 3 Year 0.36
Over 1 Month
13.87% down
Over 1 Year
9.85% down
Over 3 Months
38.55% down
Over 3 Years
0.00% down
Over 6 Months
14.77% down
Over 5 Years
0.00% down

ONESOURCE SPECL PHARMA L Corporate Actions

Top Gainers

Top Losers

ONESOURCE SPECL PHARMA L Share Price

Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies. The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,. Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

In FY 2024-25, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024. Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively.

Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies. In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re. 1/- each have been allotted and issued.

At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats. It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics. Company has 5 globally compliant Manufacturing Facilities. Customer list includes some of the top pharmaceutical generic companies, innovator pharmaceutical and biopharmaceutical companies, small biotechs and dedicated R&D houses, spread across the globe.

Company completed execution of high-value projects across Biologics, Injectables, and Oral Technologies in FY 2025.

Parent organization Indian Private
NSE symbol ONESOURCE
Founded 2007
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of OneSource Specialty Pharma Ltd?

Answer Field

OneSource Specialty Pharma Ltd share price is for NSE ₹ 1,779.30 & for BSE ₹ 1,779.30 as on May 26 2026 12:43 PM.

What is the Market Cap of OneSource Specialty Pharma Ltd Share?

Answer Field

The market cap of OneSource Specialty Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 26 2026 12:43 PM.

What is the 52 Week High and Low of OneSource Specialty Pharma Ltd?

Answer Field

The 52 Week High and Low of OneSource Specialty Pharma Ltd for NSE is ₹ 2,248.00 and ₹ 1,057.00 and for BSE is ₹ 2,249.65 and ₹ 1,075.00.

What is 1 year return for OneSource Specialty Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 2.39%.

What is the P/E Ratio of OneSource Specialty Pharma Ltd Share?

Answer Field

As on May 26 2026 12:43 PM the price-to-earnings (PE) ratio for OneSource Specialty Pharma Ltd share is 978.00.

What is the PB ratio of OneSource Specialty Pharma Ltd Share?

Answer Field

As on May 26 2026 12:43 PM, the price-to-book (PB) ratio for OneSource Specialty Pharma Ltd share is 519.00.

How to Buy OneSource Specialty Pharma Ltd Share?

Answer Field

You can trade in OneSource Specialty Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy OneSource Specialty Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy OneSource Specialty Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “OneSource Specialty Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|